ERBB2 and neoplasm: We have recently generated a prognostic signature for HER2+:ERα− BC based on the identification of genes that were differentially expressed in a tumor-initiating cell (TIC)-enriched fraction versus non-TIC fraction from a mouse model of HER2+ BC (MMTV-Hers/Neu).